Scoopfeeds — Intelligent news, curated.
ai

A plan to make drugs in orbit is going commercial

MIT Technology Review · May 13, 2026, 10:00 AM

Why this matters: a development in AI with implications for how people work, create, and decide.

Varda Space Industries, a startup that’s been pitching its ability to perform drug experiments in space, says it has signed up the pharmaceutical company United Therapeutics in what may be remembered as a notable step toward in-orbit manufacturing. The idea of building things in outer space for use on Earth has so far been explored mostly on board the International Space Station, and only in small-scale experiments backed by governments. But Varda, based in El Segundo, California, is now telling drug companies it has a practical, and repeatable, way to produce novel molecules in microgravity. “This is the first commercial path to products made in space,” says Michael Reilly, Varda’s chief strategy officer. The scientific idea is that chemical mixtures have different properties under weightless conditions. For instance, water will hang together in a wiggly sphere, since without gravity, surface tension is the strongest force present. The plan is to launch versions of United Therapeutics’ drugs into orbit, where they can be allowed to form solid crystals. The hope is that in microgravity, they’ll take on atomic arrangements not seen on Earth, possibly leading to new versions with improved stability or other valuable properties. United is led by CEO Martine Rothblatt, who worked on early telecommunications satellites. Since then, she’s built a multibillion-dollar health franchise with a succession of drugs to treat a lung disease called pulmonary arterial hypertension, which her daughter suffers from, and a subsidiary developing genetically modified pigs as a source of organs for transplantation. Rothblatt says space could be the next step if orbital conditions permit United to identify “even more amazing” versions of its drugs. Space to reformulate Pharmaceutical companies often try to keep their blockbuster franchises alive by creating improved versions of drugs or reformulating them—for example, making the switch from a pill to an inhaled version, as United has done

Article preview — originally published by MIT Technology Review. Full story at the source.
Read full story on MIT Technology Review → More top stories
Aggregated and edited by the Scoop newsroom. We surface news from MIT Technology Review alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop